NCT00528684 - Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

June 30, 2010

Conditions

Malignant Glioma

Interventions

BIOLOGICAL

REOLYSIN®

REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.

Trial Locations (3)

35294

University of Alabama at Birmingham, Birmingham

43210

The Ohio State University Medical Center and Arthur G. James Cancer Hospital and Richard J. Solove Research Center, Columbus

90048

Cedars-Sinai Medical Center, Los Angeles